Experience the Quality With Free AOCNP Exam Questions That Helps Candidates Pass

Breakthrough CINV requires adding or intensifying agents from a different pharmacologic class than those used for prophylaxis. Escalating olanzapine to 10 mg daily for 2–3 days is effective for refractory nausea (often harder to control than emesis) and can be combined with PRN dopamine antagonists (metoclopramide or prochlorperazine) for synergistic effect. Rotating or stacking 5-HT3 antagonists alone (Option A) offers limited benefit because serotonin pathways are already blocked and delayed-phase emesis is more substance P–mediated. Scopolamine (Option C) targets vestibular pathways and is not first-line for chemotherapy-related mechanisms. Promethazine alone (Option D) provides sedation but is inferior as monotherapy for breakthrough symptoms. APRN management includes correcting dehydration/electrolytes, assessing for mucositis or gastroparesis, reinforcing small frequent meals, and reviewing interacting meds (opioids, antibiotics). For future cycles, consider optimizing delayed-phase coverage (extend dexamethasone, scheduled olanzapine) or using alternative NK1 RA schedules. Document response and adverse effects (somnolence, orthostasis) and provide clear home rescue plans.

Oral oncolytics have narrow therapeutic windows and complex DDI profiles (acid-reducing agents, CYP3A modulators, QT-prolonging drugs). A reliable system couples rigorous medication reconciliation (including OTCs and supplements) with oncology-specific EHR alerts that are curated to minimize noise yet flag high-risk interactions with actionable alternatives (e.g., H2 blockers with timing adjustments instead of PPIs). Embedding a pharmacist-APRN collaborative protocol ensures expert review at initiation and dose changes, while standardized patient education teaches what to avoid and who to call before new meds. A rapid consult pathway (pharmacy/oncology) resolves urgent questions without delaying therapy. Reliance on memory (Option A) and static handouts (Option D) are unsafe. Disabling alerts (Option C) increases error risk. The APRN also monitors for clinical signals of DDIs (toxicity, loss of efficacy), documents counseling, and measures process outcomes (percent reconciled meds, intercepted interactions) to drive continuous improvement.

Immune-mediated colitis is a common checkpoint inhibitor toxicity. After excluding infection (C. difficile, pathogens), grade ≥3 diarrhea warrants holding immunotherapy and initiating systemic steroids—prednisone 1–2 mg/kg/day or IV methylprednisolone for severe cases—with a slow taper over at least 4–6 weeks after improvement to ≤grade 1. Failure to respond within 48–72 hours should prompt biologic therapy: infliximab is standard unless contraindicated (e.g., sepsis, perforation), while vedolizumab is an effective gut-selective alternative. Supportive care includes IV fluids/electrolyte repletion, nutritional support, and pain control; avoid antidiarrheals alone in high-grade disease. Continuing ICI (Option A) risks perforation and hospitalization. Antibiotics alone (Option C) do not address immune-driven inflammation absent infection. Rechallenge decisions depend on severity/response; automatic restart (Option D) is unsafe. The APRN coordinates stool testing, imaging, early GI involvement, steroid monitoring (glucose, infection risk), and patient education on red flags (blood in stool, fever, severe pain) while documenting grade and response for future treatment planning.

Hypercalcemia from calcitriol (1,25-dihydroxyvitamin D) overproduction—seen with certain lymphomas—responds particularly well to glucocorticoids, which inhibit extrarenal calcitriol synthesis and intestinal calcium absorption. Initial management includes aggressive isotonic IV fluids to correct dehydration and enhance calciuresis. Calcitonin provides a rapid but transient reduction and can bridge to definitive control. Bisphosphonates or denosumab may be added to suppress bone resorption, though in calcitriol-mediated cases steroids are pivotal. Calcitonin alone (Option C) relieves symptoms briefly but is insufficient. Dialysis (Option D) is reserved for refractory, life-threatening hypercalcemia with renal failure or fluid overload. The APRN should monitor electrolytes (risk of hypophosphatemia), mental status, urine output, and consider lymphoma-directed therapy for durable control. Educate on hydration and review medications that raise calcium (thiazides, vitamin D), adjusting as needed.

Lynch syndrome confers a markedly elevated lifetime risk for colorectal cancer and accelerated adenoma–carcinoma sequence. Evidence-based surveillance begins early—typically age 20–25 years or 2–5 years before the youngest family case—and is repeated at 1–2 year intervals, with shorter intervals for prior adenomas, poor prep, or additional risk factors. Colonoscopy is preferred over noninvasive stool testing (Option C) due to higher sensitivity for flat lesions and the need for immediate polypectomy. CT colonography (Option D) lacks therapeutic capability and exposes to radiation; it is considered only when colonoscopy is incomplete. Waiting until 50 and using 10-year intervals (Option A) applies to average risk and would miss early, rapidly progressing lesions in Lynch. The APRN should coordinate genetic counseling, discuss gynecologic risk management (endometrial/ovarian), aspirin chemoprevention considerations, and cascade testing for relatives. Document a survivorship plan specifying intervals, endoscopist experience needs, and symptom red flags warranting earlier evaluation.